topimage

PLATFORM FOR AUTOLOGOUS CELL THERAPIES

Impact at a Glance


SUPERIOR HANDLING

  • Fully automated system
  • Fast processing time
  • Product/therapy is ready-to-use straight out of the centrifuge

UNRIVALLED RESULTS WITH HIGH REPRODUCIBILITY 1

  • High platelet yield
  • High yield of growth factors and anti-inflammatory cytokines
  • Presence and absence of leukocytes determined by user
  • Adjustable final volume

HIGH FLEXIBILITY

  • A multitude of different autologous cell therapies with just one system
  • Physicians can save their own individualized programs
  • Use across medical specialties

MAXIMUM SAFETY

  • Closed system
  • Scientifically tested IMPACT programs 1
  • Reliability and quality Made in Germany

1 Scientifically tested serum concentrations (TU Munich)

PLATFORM FOR AUTOLOGOUS CELL THERAPIES

One system – many therapeutic options

The IMPACT system offers the user the opportunity of producing various autologous cell therapies with only one platform. Autologous cell therapies – internationally also known as orthobiologics – use the body’s own physiological regeneration mechanisms. They contain growth factors, anti-inflammatory cytokines or stem cells in concentrated form, for example. After injection to the defect, they assist the body in an absolutely natural way to heal the injured tissue.

The innovative technology of IMPACT permits the production of variable concentrations of leukocytes and thrombocytes. And that, by means of a very simple automated production process. Scientifically tested IMPACT programs with specific parameters are recommended for each therapeutic objective. In addition, the system also permits the physician to define and store own program variants.

With the IMPACT system the physician can offer numerous different autologous cell therapies. Thus, the patients’ individual therapeutic needs are met even better.

 

Very easy handling

Reliable technology for reproducible results

IMPACT centrifuges and separates the requested blood fractions fully automated and in a closed system. The sensitivity of the optical sensor installed can be adjusted. Thus, the optical sensor separates reliably and precisely. The syringe with the patient’s blood is laid in, and after the program has been completed, the requested autologous “ready-to-use” blood product is removed.

 

Technical data

Dimensions (H × W × D): 456 x 555 x 707 mm

Capacity: 2 x 12 ml

Max. RPM: 2.800

Max. RCF: 940

Operation by intuitive user-friendly touch display

Innovative technology

 

ONE SYSTEM – MANY THERAPEUTIC OPTIONS

Innovative and customizable production of autologous cell therapies – with one system only

The IMPACT system can be used to produce a number of different autologous cell therapies at the push of a button. The selection is made depending on the respective therapeutic objective. Single-use treatment sets are available for different therapeutic applications:


IMPACT PRP – Platelet Rich Plasma

Without anticoagulant for the production of slightly concentrated platelet-rich plasma

 
 

IMPACT APC – Autologous Platelet Concentrate

With anticoagulant for the production of highly concentrated platelet concentrate

More information (PDF Download)

 

IMPACT ACS – Autologous Conditioned Serum

For the production of an autologous conditioned serum

More information (PDF Download)

 

Other treatment sets in preparation

 

AUTOLOGOUS CELL THERAPIES

Use of the physiological regeneration process

Autologous cell therapies make use of the natural endogenous mechanisms for the regeneration and healing of injured tissue.

The body’s response to an injury is a complex healing cascade in order to heal the wound as quickly as possible. To understand how this regeneration process runs down, the cellular level has to be looked into.

Histologically, three types of cells can be discerned in the blood: Erythrocytes responsible for the transportation of oxygen and carbon dioxide; leukocytes which divide up into different types and regulate the immune defense; as well as thrombocytes, also referred to as blood platelets

Platelets are responsible for hemostasis, and mediate the first phases of wound healing. In this phase, platelets aggregate and form the blood clot. In addition, growth factors are released by degranulation of thrombocytes.

The release of cellular growth factors supports healing by

  • Attracting undifferentiated cells to the site of the injury (chemoattraction and migration) and by stimulating mitosis of undifferentiated cells (proliferation)
  • Suppressing cytokine release, thus reducing anti-inflamma- tory reactions
  • Attracting macrophages for the improvement of tissue healing and regeneration
  • Supporting capillary growth and accelerating epithelization

Leukocytes form several cytokines, referred to as interleukins. They mediate between leukocytes and play an important role in immune defense.

This is where autologous cell therapies come in: From the patient’s whole blood those cells, cytokines or growth factors are isolated and concentrated, which promise the best therapeutic outcome for the initial diagnosis. They are brought to the site of the injury or defect, and support the physiological regeneration and healing process.

IMPACT is the innovative platform for autologous cell therapies and permits the largest possible diversity of therapies and flexibility.

Autologe Zelltherapie

Registration for the doctors area